Two posters featuring highly significant head to head data for Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.064%) vs Taclonex® Topical Suspension were shown at the Maui ...

EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference.

Wynzora ® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is now available for the topical treatment of plaque psoriasis in adults 18 years of age and older.. Wynzora is a ...

Abonados. España; Internacional; Economía; Deportes; Cultura; Sociedad; Autonomías. Andalucía; Aragón; Cantabria; Castilla-La Mancha ...

A novel formulation of calcipotriene (CAL), betamethasone dipropionate (BDP) cream was found to be more effective, provide superior quality of life, and safe in patients with psoriasis, compared ...

A 47-year-old female presents with vulvar dermatitis due to clotramizole in an antifungal cream. X. No Results. No Results. ... macular erythema from one clotrimazole-betamethasone cream, ...

COPENHAGEN, Denmark, July 22, 2020 / B3C newswire / --MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard of topical therapies for chronic inflammatory conditions, ...

Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for once-daily topical treatment of plaque psoriasis in adults 18 years of age or ...

EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference ...

EPI Health, LLC, a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists and MC2 Therapeutics, a commercial stage pharmaceutical company ...